Ninety One UK Ltd Lowers Stake in Edwards Lifesciences Corporation $EW

Ninety One UK Ltd lessened its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 0.9% during the 2nd quarter, Holdings Channel reports. The fund owned 6,939,542 shares of the medical research company’s stock after selling 64,875 shares during the period. Edwards Lifesciences comprises approximately 1.3% of Ninety One UK Ltd’s holdings, making the stock its 23rd largest position. Ninety One UK Ltd’s holdings in Edwards Lifesciences were worth $542,741,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Brighton Jones LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at about $266,000. Versant Capital Management Inc lifted its position in shares of Edwards Lifesciences by 9.3% during the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company’s stock valued at $123,000 after buying an additional 145 shares during the last quarter. AdvisorNet Financial Inc boosted its holdings in shares of Edwards Lifesciences by 11.5% in the 1st quarter. AdvisorNet Financial Inc now owns 1,663 shares of the medical research company’s stock valued at $121,000 after buying an additional 172 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Edwards Lifesciences by 7,061.2% in the 1st quarter. GAMMA Investing LLC now owns 340,946 shares of the medical research company’s stock valued at $24,712,000 after buying an additional 336,185 shares in the last quarter. Finally, Rhumbline Advisers grew its position in shares of Edwards Lifesciences by 4.1% in the 1st quarter. Rhumbline Advisers now owns 1,130,154 shares of the medical research company’s stock worth $81,913,000 after buying an additional 44,249 shares during the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW opened at $77.84 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The stock has a 50-day moving average of $78.54 and a two-hundred day moving average of $75.84. The stock has a market cap of $45.70 billion, a P/E ratio of 11.20, a P/E/G ratio of 3.71 and a beta of 1.07. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the business posted $0.70 earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Piper Sandler raised their target price on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. BTIG Research upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price objective for the company in a report on Tuesday, July 29th. Wells Fargo & Company boosted their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Thursday, August 7th. Canaccord Genuity Group upped their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a research report on Friday, July 25th. Finally, Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday. Three investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $86.61.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.